Measurable residual disease (MRD) is emerging as an important prognostic marker in the management of multiple myeloma. Promising clinical evidence from trials, such as the MYELOMA XI trial, has linked MRD-negativity to improved outcomes in myeloma. Whilst research into MRD as a prognostic marker continues, MRD is further being explored as a tool to guide the adaptive treatment of patients, such as by intensifying treatment for MRD-positive patients, or by de-escalating treatment for MRD-negative patients. Future trials investigating the relative safety and efficacy of MRD-guided adaptive treatment will help to determine the optimal role of MRD in multiple myeloma.
In this podcast, Natalie Callander, MD, of the University of Wisconsin School of Medicine and Public Health, Madison, WI, Luciano Costa, MD, PhD, of the UAB School of Medicine, Birmingham, AL, Fredrik Schjesvold, MD, PhD, of the Oslo Myeloma Center Oslo University, Oslo, Norway, Lanny Kirsch, MD, Senior Vice President in Translational Medicine at Adaptive Biotechnologies, Seattle, WA, and Philippe Moreau, MD, of the Nantes University Hospital, Nantes, France, discuss the latest data on the use of MRD in the management and treatment of multiple myeloma, as presented at the 18th International Myeloma Workshop (IMW 2021).
The growing role of immunotherapy in the treatment of ALL & moving away from stem cell transplantation
The current status of CAR-T therapy in CLL and challenges in this space
Managing and treating GvHD and other post-transplant complications
The role of MRD in multiple myeloma
Novel immune therapies in MDS and challenges in this space
NHL highlights at ASH 2022: Updates in MCL, the role of transplantation, and novel bispecific antibodies
MPN highlights at ASH 2022: Novel agents, combinations & the role of immunotherapy
T-cell lymphoma highlights at ASH 2022: Unmet needs, clinical trial updates & future outlooks
The importance of CD47 in MDS and other targets of interest
CLL highlights at ASH 2022: Clinical trial updates, novel BTK inhibitors & combination therapy
Myeloma highlights at ASH 2022: Improving access to CAR-T therapy & future outlooks
Highlights in MDS at ASH 2022: Treating lower-risk & higher-risk disease, trial updates, & more
iwNHL Session V: Novel therapies in NHL - the role of ADCs
iwAL 2022 Session V: Mechanisms of resistance to targeted therapies in AML
The importance of genomic testing in CLL and its role in clinical decision-making
iwNHL Session IV: T-cell therapies for NHL: CAR-T therapies & third-party EBV T-cells
Key updates in CLL: novel treatment strategies, the changing role of chemotherapy, and more
iwAL 2022 Session IV: The evolving treatment landscape in ALL and the growing role of immunotherapies
iwNHL Session III: Exploring the optimal management of R/R follicular lymphoma in an expanding treatment landscape
iwAL 2022 Session III: Novel targets, combinations and treatment strategies in AML
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Peter Attia Drive
The Doctor’s Farmacy with Mark Hyman, M.D.